ProtoKinetix (PKTX) is a research and development company leading the way in cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide helps more cells survive longer and has the capability to change health care forever. With AAGP, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve. ProtoKinetix has harnessed a molecule found in nature with the power to transform lives and the future of health care. Founded in 2002, ProtoKinetix secured a patent for anti-aging glycopeptide (AAGP), a naturally-occurring molecule that regenerates cells for animals surviving in arctic temperatures. AAGP has gone through a series of tests in laboratories throughout Europe and North America conducted by some of the best researchers in the world. Backed by a decade of promising clinical research, all trials to date have shown that AAGP is safe, stable and effective in protecting and regenerating cells. This molecule could be the link to improved treatments for transplants, Type 1 diabetes, macular degeneration, stroke, heart disease and so much more. There is endless potential, and we’ve only seen the tip of the iceberg. Become part of the next great medical discovery.